Zijin Mining(SH:601899) Yong An Qi Huo·2025-07-25 03:50Report Industry Investment Rating - Not provided in the given content Core Viewpoints - A-shares rose strongly with the Shanghai Composite Index up 0.65% at 3605.73 points, the Shenzhen Component Index up 1.21%, and the ChiNext Index up 1.5%. Multiple sectors saw gains, with securities, energy metals, and coal industries leading the increase [1]. - Hong Kong stocks hit a new high with low intraday selling pressure. The Hang Seng Index closed up 0.51% at 25667.18 points, the Hang Seng Tech Index down 0.05%, and the Hang Seng China Enterprises Index up 0.18%. Lithium stocks rose strongly, the semiconductor industry rallied, and precious metals declined [1]. - European central banks kept interest rates unchanged and entered a wait - and - see mode. Traders reduced their bets on further interest rate cuts this year [8][12]. - The China - EU Summit achieved little. The EU called on China to open its market and address over - capacity issues [8][12]. - The US initial jobless claims fell for the sixth consecutive week, reaching the lowest level since mid - April, highlighting the resilience of the labor market [12]. Company - Specific Highlights Company Listing and Performance - Zhonghui Yuantong Bio, a vaccine company, resubmitted its listing application to the Hong Kong Stock Exchange. Its losses widened in the first quarter [10]. - Pinduoduo appointed Ernst & Young Hong Kong to audit its financial statements, which analysts believe may be a step towards listing in Hong Kong [10]. - Juzhi Technology reapplied for listing in Hong Kong. Its net profit decreased by 13.6% in the first four months of this year [10]. Company Business Moves - JD Group is in advanced talks to acquire German electronics retailer Ceconomy for about $2.6 billion [13]. - Zijin Mining is leading the bid for the African "Tongon" gold mine, with an offer potentially up to $500 million [13]. Company Ratings - Morgan Stanley re - covered CK Hutchison, giving it a "Buy" rating with a target price of HK$65, representing a 28% upside from the current price [13]. - Morgan Stanley raised the target price of China Hongqiao to HK$24.8 and reiterated its "Buy" rating [13]. Company Product Developments - China Biopharmaceutical's subsidiary, Lixin Pharmaceutical, obtained the IND approval for its innovative drug LM - 350 "CDH17 ADC" from the US FDA [13]. Company Land Transactions - Cai Wensheng of Meitu is reported to have bought a plot in Causeway Bay for HK$750 million [13]. Company Profit Projections - Lingbao Gold expects its mid - year net profit to increase by up to 3.5 times year - on - year [13]. Market Data Summaries Stock Price Changes - Various stocks in different markets showed different price changes, including those in A - shares, Hong Kong stocks, and US stocks. For example, in A - shares, stocks like HNA Holdings and Hainan Airport had significant price increases [30]. Dividends and Rights Issues - Multiple companies had dividend announcements, rights issues, or share consolidation plans. For instance, ASMPT announced a mid - year dividend of HK$0.26 [16]. Economic Indicators - US economic indicators such as long - term net TIC flows, new home starts, and consumer confidence index showed different trends. The long - term net TIC flows in May were $259.4 billion, a decrease of $7.8 billion [17].